PBM Watch Litigation & Enforcement Tracker
Live snapshot

Pharmacy Benefit Manager Accountability · June 2026

The middlemen are on trial.

A consolidated view of every active federal and state action against the pharmacy benefit managers — Caremark, Express Scripts, OptumRx and the GoodRx pricing alliance. Each status, judge, allegation and filing is tagged with a plain-English explainer. Hover anything.

Last reviewed June 11, 2026  ·  Sources: FTC Legal Library, U.S. District Court (D.R.I.), JPML, NCPA & plaintiff firms.

Recent updates
2+
Major federal proceedings running in parallel
6
PBM & pricing-platform defendants under tracking
40+
Independent-pharmacy plaintiffs consolidated in MDL 3148
$7B
Projected 10-yr patient savings cited in the ESI settlement
Parties
Status
01

Real-time status grid

Where each defendant stands in each proceeding, right now. A cell is a verdict-at-a-glance — hover for the why.

Rows = defendants
Columns = proceedings
Active / Contested Negotiating / Stayed Settled Pending ruling Not named
02

Case dossiers

The full file on each proceeding — court, judge, defendants, the legal theory, the latest docket entries, and who’s saying what.

03

State & legislative front

The courts aren’t the only battlefield. States and Congress are rewriting the rules PBMs operate under.

Executive Summary

The dam is cracking — but the biggest fights are still live.

After two years of pressure, the pharmacy-benefit-manager model is being challenged on every front at once. In February 2026 the FTC won a landmark consent settlement with Express Scripts in the insulin rebating case (Docket 9437), finalized June 10, 2026. That deal cracked the wall — and turned up the heat on Caremark and OptumRx, who are now negotiating or contesting their own exposure.

In parallel, every major PBM faces a private antitrust war: independent pharmacies allege that the GoodRx ISP let competitors fix the prices they pay pharmacies — a textbook Sherman Act §1 claim now consolidated before one judge in Rhode Island.

The throughline: regulators and pharmacies are attacking the same machinery — rebate-driven pricing and DIR-style fee clawbacks — from two directions.

  • i.One down, two to go. Express Scripts has settled the FTC insulin case. Caremark is in consent talks; OptumRx is still fighting. The FTC’s leverage is at an all-time high.
  • ii.The constitutional escape hatch failed. A federal judge rejected the PBMs’ bid to shut down the FTC’s in-house case — so the agency keeps the home-court advantage.
  • iii.The pharmacy MDL is at its hinge point. A pending motion to dismiss in MDL 3148 will decide whether the price-fixing theory survives to discovery.
  • iv.Watch arbitration. PBM contracts may force some pharmacies out of court — the single biggest threat to the class action.
  • v.For employers: settlements are forcing transparency and de-linked pricing into standard PBM contracts. The next renewal is the moment to demand it.